HXB Stock Chart & Stats
€6.09
€0.00(0.00%)
At close: 4:00 PM EDT
€6.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.09 - €6.09
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.10M
Enterprise Value€1.24
Total Cash (Recent Filing)€9.90M
Total Debt (Recent Filing)€300.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 18, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding27,724,245
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.54Price Target Upside-25.44% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.13
Revenue Forecast (FY)€85.97K
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale-up For AmpligenContracting Sterling for polymer precursor manufacture and test-method transfers materially reduces clinical supply risk and shortens timelines for ongoing and potential Phase 3 work. A secured CMO pathway supports reliable trial execution, regulatory submissions, and preserves program continuity over coming months.
Regained NYSE American Listing ComplianceRestoring compliance via financings and lifting the below-compliance flag stabilizes public listing status and preserves market access. This reduces short-to-medium-term governance risk, supports investor engagement, and preserves the company’s ability to access capital and institutional channels when needed.
Clinical Progress & Broadened Antiviral PositioningPositive clinical signals, KOL endorsements, peer-reviewed oncology publications, and orphan/regulatory designations for antiviral work create durable clinical and regulatory optionality. Multiple indication pathways (oncology and biodefense) increase addressable markets and potential partnering or non-dilutive funding opportunities.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow at roughly -$7M TTM signals structural funding needs. With FCF tracking net losses nearly one-to-one and recent deterioration, the company requires recurring external financing to sustain R&D and trials, constraining multi-cycle program execution without dilution or debt.
Minimal Revenue And Sustained LossesExtremely small revenue and deeply negative gross and operating margins reflect an early‑stage R&D profile without commercial cash flow. Persistent multi‑million dollar net losses reduce internal funding capacity and mean long‑term viability hinges on clinical success or continual external capital.
Ongoing Dilution And Financing DependenceFrequent equity offerings, warrant inducements and shareholder approval for large issuance capacity indicate sustained reliance on equity-linked financing. This pattern raises dilution risk, can limit investor confidence, and implies recurring capital events will be needed to fund trials absent revenue or partnering deals.
AIM ImmunoTech News
HXB FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest stock price was €6.09 and its highest was €6.09 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is €6.10M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Aug 18, 2026 which is in 8 days.
How were AIM ImmunoTech’s earnings last quarter?
Currently, no data Available
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Overvalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech pays a N/A dividend of €0.235 which represents an annual dividend yield of N/A. See more information on AIM ImmunoTech dividends here
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate is -0.15.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 27,724,245 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in DE:HXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
HXB Stock 12 Month Forecast
Average Price Target
€4.54
▼(-25.44% Downside)